Pexelizumab: A novel therapy for myocardial ischemia-reperfusion

Drugs of Today

Volumn 41, Issue 3, 2005, Pages 165-170

  Patel, Manesh R ^a   Granger, Christopher B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5; CYTOKINE; PEXELIZUMAB;

ACUTE HEART INFARCTION; APOPTOSIS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS GRAFT; CORONARY REPERFUSION; CYTOKINE RELEASE; DOSE RESPONSE; EPICARDIUM; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; META ANALYSIS; METABOLITE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; MYOCARDIAL REPERFUSION INJURY; TECHNOLOGY, PHARMACEUTICAL;

EID: 18244379842     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.3.892521     Document Type: Review

References (29)

1. Becker, L.C., Ambrosio, G. Myocardial consequences of reperfusion. Progr Cardiovasc Dis 1987, 30: 23-44.
2. Gottlieb, R.A., Burleson, K.O., Kloner, R.A., Babior, B.M., Engler, R.L. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994, 94: 1621-8.
3. Ambrosio, G., Flaherty, J.T., Duilio, C. et al. Oxygen radicals generated at reflow induce peroxidation of membrane lipids in reperfused hearts. J Clin Invest 1991, 87: 2056-66.
4. Forde, R.C., Fitzgerald, D.J. Reactive oxygen species and platelet activation in reperfusion injury. Circulation 1997, 95: 787-9.
5. Kloner, R.A. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993, 21: 537-45.
6. Ambrosio, G., Tritto, I. Reperfusion injury: Experimental evidence and clinical implications. Am Heart J 1999, 138 (2 Pt 2).
7. Riedemann, N.C., Ward, P.A. Complement in ischemia reperfusion injury. Am J Pathol 2003, 162: 363-7.
8. Entman, M.L., Smith, C.W. Postreperfusion inflammation: A model for reaction to injury in cardiovascular disease. Cardiovasc Res 1994, 28: 1301-11.
9. Jordan, J.E., Zhao, Z.Q., Vinten-Johansen, J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 1999, 43: 860-78.
10. Hill, J.H., Ward, P.A. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 1971, 133: 885-900.
11. Vakeva, A., Laurila, P., Meri, S. Regulation of complement membrane attack complex formation in myocardial infarction. Am J Pathol 1993, 143: 65-75.
12. Marks, R.M., Todd, R.F. 3rd, Ward, P.A. Rapid induction of neutrophil-endothelial adhesion by endothelial complement fixation. Nature 1989, 339: 314-7.
13. Maroko, P.R., Carpenter, C.B., Chiariello, M. et al. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest 1978, 61: 661-70.
14. Buerke, M., Murohara, T., Lefer, A.M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 1995, 91: 393-402.
15. de Zwaan, C., Kleine, A.H., Diris, J.H. et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002, 23: 1670-7.
16. Ross, G.D., Medof, M.E. Membrane complement receptors specific for bound fragments of C3. Adv Immunol 1985, 37: 217-67.
17. Chenoweth, D.E. The properties of human C5a anaphylatoxin. The significance of C5a formation during hemodialysis. Contrib Nephrol 1987, 59: 51-71.
18. Foreman, K.E., Vaporciyan, A.A., Bonish, B.K. et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994, 94: 1147-55.
19. Stahl, G.L., Reenstra, W.R., Frendl, G. Complement-mediated loss of endothelium-dependent relaxation of porcine coronary arteries. Role of the terminal membrane attack complex. Circ Res 1995, 76: 575-83.
20. Hamilton, K.K., Ji, Z., Rollins, S., Stewart, B.H., Sims, P.J. Regulatory control of the terminal complement proteins at the surface of human endothelial cells: Neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 1990, 76: 2572-7.
21. Vakeva, A.P., Agah, A., Rollins, S.A., Matis, L.A., Li, L., Stahl, G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: Role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998, 97: 2259-67.
22. Thomas, T.C., Rollins, S.A., Rother, R.P. et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Molec Immunol 1996, 33: 1389-401.
23. Fitch, J.C., Rollins, S., Matis, L. et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999, 100: 2499-506.
24. Chenoweth, D.E., Cooper, S.W., Hugli, T.E., Stewart, R.W., Blackstone, E.H., Kirklin, J.W. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins. New Engl J Med 1981, 304: 497-503.
25. Shernan, S.K., Fitch, J.C., Nussmeier, N.A. et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 2004, 77: 942-9; discussion 949-50.
26. Verrier, E.D., Shernan, S.K., Taylor, K.M. et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 2004, 291: 2319-27.
27. Mahaffey, K.W., Granger, C.B., Nicolau, J.C. et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003, 108: 1176-83.
28. Granger, C.B., Mahaffey, K.W., Weaver, W.D. et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003, 108: 1184-90.
29. Van de Werf, F., Armstrong, P.W., Levy, J.H. et al. Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004, 47: 474A.